Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells.

Journal of the National Cancer Institute - 1 Jul 1998

Abbott D W, Freeman M L, Holt J T

Abstract excerpt

BACKGROUND: The protein product of the BRCA2 gene mediates repair of double-strand breaks in DNA. Because a number of cancer therapies exert cytotoxic effects via the initiation of double-strand breaks, cancers comprised of cells carrying BRCA2 gene mutations may be more amenable to treatment with agents that cause such breaks. METHODS: We identified a human pancreatic adenocarcinoma cell line lacking one copy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to DNA, Neoplasm
Share to DNA Primers

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Repair

Share to Mutation

Share to Polymerase Chain Reaction

Share to Time Factors

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 9665145
DOI: 10.1093/jnci/90.13.978

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells.PMID 9665145Read ↗

DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparibSemantic proximity Read ↗

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.Semantic proximity Read ↗

Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673Semantic proximity Read ↗

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.Semantic proximity Read ↗

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.Semantic proximity Read ↗

Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53‐independent pancreatic cancer cell deathSemantic proximity Read ↗

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer XenograftsSemantic proximity Read ↗

DDB2 gene disruption leads to skin tumors and resistance to apoptosis after exposure to ultraviolet light but not a chemical carcinogenSemantic proximity Read ↗

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.Semantic proximity Read ↗

DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP InhibitorsSemantic proximity Read ↗

Small-Molecule Drugs Mimicking DNA Damage: A New Strategy for Sensitizing Tumors to RadiotherapySemantic proximity Read ↗

Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.